Alpha-fetoprotein (AFP) is a known glyco-biomarker of hepatocellular carcinoma (HCC) and identifying glycoprotein biomarkers is useful for clinical diagnosis. CD BioGlyco has established multiple methods to provide AFP detection service to our clients.

Introduction

For many years, it has been known that aberrant glycosylation is associated with various human diseases, especially cancer. Detecting cancer at an early stage that can be treated through surgery is a challenging task. One approach to discovering cancer biomarkers is to exploit the fact that glycoproteins generated by cancer cells have altered the glycan structures, although these proteins themselves are common, abundant, ubiquitous, and familiar. However, since early-stage cancer tissue may account for less than 1% of normal tissue in the relevant organ, only 1% of the associated glycoproteins in serum alter glycan structures. The development of strategies to detect these low-level glycoprotein biomarkers has an important role to reveal the biological significance of disease-associated glycosylation patterns.

An early diagnosis and effective treatment of HCC are now essential to improve the prognosis and reduce the associated economic burden. Serum AFP is by far the most widely used biomarker for HCC screening, early diagnosis, and assessment of efficacy and prognosis. The ability to rapidly detect glycan biomarkers that serve as indicators of pathologies such as infection, inflammation and cancer with high specificity and sensitivity using modern technological tools such as glycobiosensors will undoubtedly provide a better tool for early disease diagnosis.

AFP Glyco-biomarker Testing Service, Accurately Capturing Every Signal

We offer both qualitative and quantitative analysis of AFP glycoforms, allowing for the identification of novel glyco-signatures and the precise measurement of known glycoforms.

• AFP Glycoform Analysis
  Using multiple reaction monitoring (MRM) mass spectrometry (MS) technology, our company provides quantitative analysis of various glycoforms of AFP in serum. This method distinguishes between different glycoforms of AFP, such as AFP-L1, AFP-L2, and AFP-L3, and provides information on glycoform changes at specific sites, thereby improving the specificity and sensitivity of the test.
• AFP Glycosylation Analysis
  Using liquid chromatography-high resolution mass spectrometry (LC-HRMS), we provide AFP glycosylation analysis services. Our services detect different glycosylation forms of AFP, such as core fucosylation and sialylation.
• Multimarker Testing
  In addition to AFP testing, our company offers combined testing services for AFP and other tumor markers (such as CA19-9, CEA, PSA, etc.).

Workflow

Applications

• Our services can be used to detect different glycoforms of AFP (such as AFP-L1, AFP-L2, AFP-L3), study their glycosylation changes in different pathological conditions, and provide basic data for glycobiology and tumorigenesis mechanisms.
• Our services can be used to study the expression levels and glycosylation status of AFP under different physiological or pathological conditions, providing support for glycoprotein function research.
• Our services can be used to explore how AFP glycosylation modifications affect its protein structure, stability, immunogenicity, and interactions with other molecules.

Advantages of Us

• Our integrated technological platform, combining LC-MS with lectin microarrays, provides exceptional specificity in identifying subtle glycoform variations and high sensitivity for detecting even low-abundance glyco-biomarkers.
• Unlike services that only detect total AFP, we provide a detailed profile of various AFP glycoforms. This in-depth analysis offers a more nuanced understanding of biological processes and disease states
• Our service simultaneously analyzes multiple sugar types, including AFP-L1, AFP-L2, and AFP-L3, avoiding repetitive experiments and improving research efficiency.

Publication Data

Frequently Asked Questions

CD BioGlyco offers a variety of cost-effective strategies for the detection of the glycoprotein biomarker AFP, allowing clients to choose the best experimental solution for their specific project needs. If you have a demand for scientific assistance, please contact us for further consultation.

Associated Services